Kodiak Sciences Inc
KOD$122M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaPALO ALTO123 employees
Drugs in Pipeline
5
Phase 3 Programs
5
Upcoming Catalysts
3
Next Catalyst
Aug 12, 2026
7wMarket Overview
Stock performance and key metrics
KOD News
Catalyst Timeline
3 upcoming, 0 past
Drug Pipeline
KSI-101
Macular Edema Secondary to Inflammation
KSI-301
Macular Edema
Tarcocimab
Diabetic Retinopathy
Tarcocimab tedromer
Wet Age-related Macular Degeneration
Aflibercept
Wet Age-related Macular Degeneration
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KSI-101 | Phase 3 | Macular Edema Secondary to Inflammation | - | - |
KSI-301 | Phase 3 | Macular Edema | - | - |
Tarcocimab | Phase 3 | Diabetic Retinopathy | - | - |
Tarcocimab tedromer | Phase 3 | Wet Age-related Macular Degeneration | - | - |
Aflibercept | Phase 3 | Wet Age-related Macular Degeneration | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply